SARC is dedicated to driving collaborations among individuals and organizations worldwide committed to discovering, developing, and delivering the latest and most promising treatments for all types of sarcomas. |
|
|
SARC was founded in 2003 by sarcoma researchers who recognized the imperative of working together to improve outcomes for sarcoma patients. In 2023 SARC has achieved the remarkable (and yet humbling) milestone of two decades of fostering collaborative efforts among the research, clinical, and patient communities to achieve breakthroughs in sarcoma.
Our common mission remains to ultimately find a cure, and we are inspired every day by the many hands pulling together on the oars towards this aspirational goal. Please continue to view SARC as your partner and facilitator, and we always welcome the opportunity to join forces.
SARC has recently launched several efforts (see below) beyond clinical studies, including the SARC Multidisciplinary Tumor Board, SARCTALK podcast series, establishing a uniform Master Collaboration Agreement, the Catalyst Program, and the Chief Scientific and Chief Medical Officer roles. Additionally, we will be announcing more new programs and initiatives at our in-person Semiannual Meeting on June 2, 2023 leading into ASCO—please join us!
| |
|
ASCO 2023
The SARC Semiannual Meeting at ASCO will take place on Friday, June 2, 2023 at the Hyatt Centric Chicago Miracle Mile (no cost to attend, breakfast included), featuring:
a) Targeted protein degradation in sarcoma
b) Provoking sarcoma cytotoxicity and immunogenicity
- Presentations by SARC’s Career Development & Catalyst Awardees:
a) SMARCAL1 – Novel vulnerability in MYC-amplified osteosarcoma
b) Monitoring treatment response in LMS by ctDNA multi-omic assay
- Progress summaries by the Principal Investigators of SARC’s currently enrolling trials.
- Closing out the meeting with overviews of other SARC programs and initiatives.
Click the agenda below to download the agenda and register for the meeting.
| | |
|
|
ASCO Presentations
Two SARC studies, SARC037 and SARC041 have been accepted for presentations at the 2023 ASCO meeting.
Oral Poster Presentation: SARC037: Results of phase I study of trabectedin given as a 1-hour infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma by Patrick Grohar, MD, PhD (CHOP) on Sunday, June 4 at 5:04pm CST in S404. [Abstract: 11519 | Poster Bd #: 453]
Trials in Progress Poster: SARC041: A phase III randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma by Mark Dickson, MD (MSKCC) on Saturday, June 3 from 1:15pm - 4:15pm CST in Hall A. [Abstract: TPS11587 | Poster Bd #: 517a]
| | |
|
|
Site Spotlight
David Siu is a Clinical Research Coordinator with the UW Medicine / Fred Hutchinson Sarcoma Program. David is the lead coordinator on SARC041. Born and raised in Boston, David graduated from Rhodes College in Memphis, TN, and lived in Honolulu prior to settling in Seattle in 2013. He previously worked in veterinary medicine before transitioning to healthcare at Swedish Hospital, Seattle Children’s, and Fred Hutch. In his free time, he enjoys collecting rare houseplants, fishing, and hiking with his partner Andy, and two dogs.
| | |
|
|
Concept
Do you have an idea for a multi-center clinical trial or research study? Whether your idea is fully developed, or you need assistance, SARC is here to help. Follow the link below if you would like SARC’s assistance/ collaboration to develop and implement your vision.
| |
SARCTALK is a podcast series (Spotify, Apple, YouTube), hosted by Dr. Scott Okuno (SARC Chief Medical Officer) featuring conversations with sarcoma investigators and patients on research and ways to accelerate progress. Be sure to subscribe on Spotify or Apple Podcasts. | |
|
The March podcast featured Denise Robinson from the EHE Foundation. Denise joins Dr. Scott Okuno to talk about EHE, research, and patient advocacy. Listen here.
The April podcast was a three part series that was recorded at the in-person research advocacy council meeting in February.
Part 1 features Dr. Mitch Achee, MD (National Leiomyosarcoma Foundation), Caralynn Hampson (SARC), and Allison Sole (Alan B. Slifka Foundation) speaking on the impact of advocacy groups on sarcoma research and patient support. Listen here.
Part 2 features Dr. Yvette Ho, MD, Dr. Erica Giles, MD, and Dr. Jessica Jones, MD from the UT Houston Sarcoma Team. They discussed multidisciplinary care teams, community outreach, and patient care. Listen here.
Part 3 features Annie Achee (National Leiomyosarcoma Foundation), Lennie Woods (Clear Cell Sarcoma Foundation), and Peter Fantozzi (Northwest Sarcoma Foundation). They talk about the importance of bringing sarcoma advocacy groups together. Listen here.
| | |
|
|
SARC Multidisciplinary Tumor Board (STMB)
The SMTB is a national, virtual meeting structured to provide innovative multidisciplinary discussion for adults and children diagnosed with sarcoma at any stage of the disease.
The SMTB brings together sarcoma experts across multiple institutions and states to discuss cases and provide insights, simultaneously complementing and expanding the geographic reach of institutional or regional tumor boards.
Moderated by Dr. Scott Okuno, Chief Medical Officer of SARC and Professor of Oncology at Mayo Clinic, the SMTB provides educational feedback from a team of experts from a wide range of specialties in sarcoma from surgical oncology, orthopedic oncology, medical oncology, radiation oncology, pediatric oncology, pathology, and radiology.
Physicians: to find out more and to submit a case, please follow the link below
| |
|
ABOUT SARC
SARC (Sarcoma Alliance for Research through Collaboration) is a non-profit organization dedicated to the development and support of research for the prevention, treatment, and cure of sarcoma – a cancer of the bone and connective tissues of the body.
SARC was formed in 2003 to conduct innovative and rigorous sarcoma research to advance the care of patients. Today, SARC collaborators include field-leading sarcoma physicians and researchers across the globe, working together to develop new strategies to improve outcomes for sarcoma patients.
| | | | |
